FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GLENMARK

506.95
+14.25 (2.89%)
Updated 03:29 18/09 IST

GLENMARK Buy or Sell - FrontPage Forums

5 Users have submitted 5 trade ideas of Rs. 147,626 for GLENMARK
Disclaimer
100% Bullish
0% Bearish

GLENMARK Buy or Sell - Brokerage Reports

No. of reports in last year
5
No. of analysts
3
Average Consensus Forecast
370.6
Consensus Potential
-33.03%
See GLENMARK Share Price Targets >>

GLENMARK Ratings

Long term GLENMARK rating by FrontPage users
3.1/5 (7 Ratings)
Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?

  1. Home
  2. GLENMARK Forum

GLENMARK Share Price Discussion

N
Reputation: 6,008 • Today 7:51 AM
Stock market update: BSE MidCap index gains nearly 1%; Natco Pharma surges 17%
The index was trading 0.91 per cent up at 15146.23.
The Economic Times
Like
Reply
I
Reputation: 110,906 • Today 7:50 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 21900 PE
Entry Price
₹165
Price@Trade
₹205.2
Target Price
₹190
Stop Price
₹160
Valid Till
Sep 18, 2020 3:20 AM
Margin
₹1,650,000 approx for 10000 Qty
Status
Waiting for entry
Like
Reply
D
Reputation: -16,449 • Today 7:50 AM

Type
Buy
Instrument
DRREDDY SEP20 5600 CE
Entry Price
₹101.55
Price@Trade
₹101.55
Target Price
₹250
Stop Price
₹50
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹25,387.5 approx for 250 Qty
Status
Active
Like
Reply
S
Reputation: 34 • Today 7:50 AM

Type
Buy
Instrument
GOLDM 05OCT20 FUT
Entry Price
₹51,650
Price@Trade
₹51,663
Target Price
₹51,780
Stop Price
₹51,600
Valid Till
Sep 18, 2020 11:20 AM
Margin
₹37,358.88 approx for 10 Qty
Status
Waiting for entry
Like
Reply
F
Reputation: -15,778 • Today 7:50 AM

Type
Sell
Instrument
DRREDDY SEP20 FUT
Entry Price
₹5,450  5435.0
Price@Trade
₹5,431.5
Target Price
₹5,400
Stop Price
₹5,500
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹274,459.38 approx for 250 Qty
Status
Waiting for entry
Like
Reply (1)
See all replies
faisal @faisal-SJlScn9Gv
Today 7:50 AM

Update
Entry Price Modified
Price @ Update
₹5,428.7
Original Entry Price
₹5,450
New Entry Price
5435.0
9
Reputation: 6,566 • Today 7:50 AM

Type
Buy
Instrument
BIOCON OCT20 FUT
Entry Price
₹460.75
Price@Trade
₹460.75
Target Price
₹480
Stop Price
₹449
Valid Till
Oct 29, 2020 3:20 AM
Margin
₹354,513.38 approx for 2300 Qty
Status
Active
Like
Reply
Aggarwal in MCX-GOLD
It is better to book profit then waiting for th...

Yesterday is very bad day as all calls going sl,but today all 3calls 2gold and natural gas are in profit #GOLD
Like
Reply
A
Reputation: -91 • Today 7:49 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 22000 PE
Entry Price
₹192
Price@Trade
₹199.35
Target Price
₹195
Stop Price
₹190
Valid Till
Sep 18, 2020 3:20 AM
Margin
₹192,000 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹190
Net P&L
-₹2,000 (-1.04%)
Like
Reply (2)
See all replies
TrackerBot @trackerbot
Today 7:50 AM

Update
Trade Entered
Entry Price
₹192
TrackerBot @trackerbot
Today 7:50 AM

Update
Stoploss Hit
Exit Price
₹190
Z
Reputation: 1,144 • Today 7:49 AM

Type
Buy
Instrument
HEROMOTOCO SEP20 FUT
Entry Price
₹3,100
Price@Trade
₹3,111.85
Target Price
₹3,159
Stop Price
₹3,084
Valid Till
Sep 18, 2020 3:20 AM
Margin
₹242,938.42 approx for 300 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Zishan Ahmad @zishanahmad
Today 7:50 AM

Update
Exited before entry
Price @ Update
₹3,107.15
M
Reputation: 4,837 • Today 7:49 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 22800 CE
Entry Price
₹171  ₹166.45
Price@Trade
₹171.7
Target Price
₹199
Stop Price
₹150
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹416,125 approx for 2500 Qty
Status
Active
Like
Reply (2)
See all replies
Mrc The Boss @Mrc
Today 7:49 AM

Update
Entry Price Modified
Price @ Update
₹166.45
Original Entry Price
₹171
New Entry Price
₹166.45
TrackerBot @trackerbot
Today 7:50 AM

Update
Trade Entered
Entry Price
₹166.45
S
Reputation: -4,160 • Today 7:49 AM

Type
Buy
Instrument
DRREDDY SEP20 5650 CE
Entry Price
₹95  ₹97
Price@Trade
₹96.5
Target Price
₹200
Stop Price
₹50
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹242,500 approx for 2500 Qty
Status
Active
Like
Reply (2)
See all replies
Sam @sam-SJNbB1jzP
Today 7:49 AM

Update
Entry Price Modified
Price @ Update
₹97
Original Entry Price
₹95
New Entry Price
₹97
TrackerBot @trackerbot
Today 7:50 AM

Update
Trade Entered
Entry Price
₹97
C
Reputation: 2,402 • Today 7:48 AM

Type
Buy
Instrument
ZINC 30SEP20 FUT
Entry Price
₹196.3
Price@Trade
₹196.45
Target Price
₹197.5
Stop Price
₹195.3
Valid Till
Sep 18, 2020 11:20 AM
Margin
₹112,278.13 approx for 5000 Qty
Status
Waiting for entry
Like
Reply
Aggarwal in MCX-GOLD
New trade: Buy GOLD 05OCT20 FUT, CMP@51498, Ent...

It is better to book profit then waiting for the target. #GOLD
Like
Reply
N
Reputation: 933 • Today 7:48 AM

Type
Sell
Instrument
RELIANCE SEP20 FUT
Entry Price
₹2,311
Price@Trade
₹2,313.55
Target Price
₹2,295
Stop Price
₹2,325
Valid Till
Sep 21, 2020 3:20 AM
Margin
₹608,781.99 approx for 1010 Qty
Status
Waiting for entry
Like
Reply
I
Reputation: 110,906 • Today 7:48 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 21900 PE
Entry Price
₹155
Price@Trade
₹158.95
Target Price
₹160
Stop Price
₹150
Valid Till
Sep 18, 2020 3:20 AM
Margin
₹3,100,000 approx for 20000 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Index Options @indexoptions
Today 7:49 AM

Update
Exited before entry
Price @ Update
₹162.6

Type
Buy
Instrument
NTPC SEP20 88 CE
Entry Price
₹2.65
Price@Trade
₹2.65
Target Price
₹7
Stop Price
₹0
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹15,105 approx for 5700 Qty
Status
Active
Like
Reply
M
Reputation: -2,021 • Today 7:46 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 22200 PE
Entry Price
₹260.2
Price@Trade
₹260.2
Target Price
₹350
Stop Price
₹180
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹6,505 approx for 25 Qty
Status
Active
Like
Reply
R
Reputation: -24,241 • Today 7:46 AM

Type
Buy
Instrument
NIFTY 24SEP20 11600 PE
Entry Price
₹105.15
Price@Trade
₹105.15
Target Price
₹125
Stop Price
₹97
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹630,900 approx for 6000 Qty
Status
Active
Like
Reply
A
Reputation: -716 • Today 7:46 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 22100 PE
Entry Price
₹220
Price@Trade
₹225
Target Price
₹280
Stop Price
₹200  210.0
Valid Till
Sep 18, 2020 3:20 AM
Margin
₹5,500 approx for 25 Qty
Status
Active
Like
Reply (2)
See all replies
TrackerBot @trackerbot
Today 7:47 AM

Update
Trade Entered
Entry Price
₹220
Anoop Goyal @anoopgoyal
Today 7:48 AM

Update
Stoploss Trailed
Price @ Update
₹229.15
Original SL
₹200
New SL
210.0

Type
Sell
Instrument
BANKNIFTY 24SEP20 23000 CE
Entry Price
₹120.9
Price@Trade
₹120.9
Target Price
₹1
Stop Price
₹220
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹813,630.2 approx for 200 Qty
Status
Active
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-Aug-20Prabhudas LilladherSell365
    4-Mar-20Nirmal BangBuy390
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 18495.05518.45495.05508.9
    Sep 17498.35503485.45492.7
    Sep 16495503.8488.35499.8
    Sep 15485.1499.75483493.6
    Sep 14487492.2476482.85
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹484.3
    30 Day Moving Average₹481.27
    50 Day Moving Average₹460.34
    100 Day Moving Average₹422.82
    200 Day Moving Average₹364.53
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Today 5:51 AM
    Stock market news: Glenmark Pharma shares jump 4%
    The Economic Times
    NewsBot
    Sep 11 10:23 AM
    Quant Pick - Glenmark Pharma: ICICI Direct
    Moneycontrol
    NewsBot
    Aug 26 7:06 AM
    US charges Teva Pharmaceutical Industries Ltd in generic drugs price-fixing probe
    The Economic Times
    NewsBot
    Aug 21 7:48 AM
    Buy Glenmark Pharma; target of Rs 576 KRChoksey
    Moneycontrol
    NewsBot
    Aug 20 7:53 AM
    To raise funds, Glenmark to divest stake in drug development arm Ichnos
    Moneycontrol
    NewsBot
    Aug 20 7:18 AM
    Buy Glenmark Pharma; target of Rs 575: Emkay Global Financial
    Moneycontrol
    NewsBot
    Aug 20 7:13 AM
    Neutral Glenmark Pharma; target of Rs 495: Motilal Oswal
    Moneycontrol
    NewsBot
    Aug 20 6:13 AM
    Sell Glenmark Pharmaceuticals; target of Rs 365: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Aug 19 4:43 AM
    Buy Glenmark Pharmaceuticals; target of Rs 560: ICICI Direct
    Moneycontrol
    NewsBot
    Aug 18 3:48 AM
    Glenmark Pharma shares trade lower after CLSA retains 'sell'
    Moneycontrol
  • GLENMARK - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020